Cannabidiol in Bipolar Depression – An 8-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Cannabidiol as Add-on Therapy in Bipolar Depression - CannaBiD

Charité - Universitätsmedizin Berlin, Campus Mitte0 个研究点目标入组 126 人开始时间: 2017年7月19日最近更新: 2024年8月19日

研究概览

暂无简介。

•male and female patients between 18 – 65 years
•- Bipolar Depression (DSM-IV)
•- Hamilton-Rating-Depression-Scale-17 > 17
•- stable optimized treatment with at least one medication for long term treatment of bipolar disorder according to the German S3-guidelines, sufficient dosage
•- YMRS < 12
•- written informed consent
•- capability to give informed consent
•- negative pregnancy test
•- highly effective method of contraception

•- pregnant or nursing women
•- serious suicidal risk or harm for others
•- inpatient treatment by legal order (PsychKG/BGB)
•- psychotic features or rapid cycling
•- relevant psychatric comorbidity such as dementia, delir, alcohol or illicit substance dependency with ongoing consumption, history of schizophrenia/ schizoaffective disorder, mental retardation
•- current treatment with antidepressive agents that cannot be discontinued
•- Treatment with quetiapine
•- non compensated thyroid disease
•- any clinical significant medical condition which will be considered unstable”
•- a known hepatitis type B/C, a known HIV infection, a known malignant disorder
•- missing contraception for men and women
•- a known intolerance to Cannabinoids
•- receiving therapy with a strong CYP3A4 inductor or inhibitor (e.g. carbamazepine)

发起方

Charité - Universitätsmedizin Berlin, Campus Mitte